<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-FOT-2834</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2834</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Особенности иммунного статуса больных с острым коронарным синдромом, перенесших СOVID-19, в зависимости от числа цитотоксических Т-лимфоцитов (CD8+)</article-title><trans-title-group xml:lang="en"><trans-title>Features of the immune status of patients with acute coronary syndrome who underwent СOVID-19, depending on the number of cytotoxic T lymphocytes (CD8+)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафронова</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Safronova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сафронова Э.А. – к.м.н., доцент кафедры поликлинической терапии и клинической фармакологии</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Safronova E.A., PhD (Medicine), Associate Professor, Department of Polyclinic Therapy and Clinical Pharmacology </p><p>Chelyabinsk</p></bio><email xlink:type="simple">safronovaeleonora68@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рябова Л.В. – д.м.н., доцент, профессор кафедры безопасности жизнедеятельности, медицины катастроф, скорой и неотложной медицинской помощи </p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Ryabova L.V., PhD, MD (Medicine), Associate Professor, Professor, Department of Life Safety, Disaster Medicine, Emergency Medicine </p><p>Chelyabinsk</p></bio><email xlink:type="simple">lianarabowa@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зурочка</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zurochka</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зурочка А.В. – д.м.н., профессор, заслуженный деятель науки Российской Федерации, ведущий научный сотрудник лаборатории иммунологии воспаления; заведующий лабораторией биотехнологий Российско-китайского центра </p><p>г. Екатеринбург;г. Челябинск</p></bio><bio xml:lang="en"><p>Zurochka A.V., PhD, MD (Medicine), Professor, Honored Worker of Science of the Russian Federation, Leading Research Associate, Laboratory of Inflammation Immunology; Head, Biotechnology Laboratory, Russian-Chinese Center</p><p>Yekaterinburg; Chelyabinsk</p></bio><email xlink:type="simple">av_zurochka@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН «Институт иммунологии и физиологии» Уральского отделения Российской академии наук;&#13;
ФГАОУ ВО «Южно-Уральский государственный университет (национальный исследовательский университет)»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Immunology and Physiology, Ural Branch, Russian Academy of Science;&#13;
South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>06</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><fpage>785</fpage><lpage>790</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сафронова Э.А., Рябова Л.В., Зурочка А.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Сафронова Э.А., Рябова Л.В., Зурочка А.В.</copyright-holder><copyright-holder xml:lang="en">Safronova E.A., Ryabova L.V., Zurochka A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2834">https://www.mimmun.ru/mimmun/article/view/2834</self-uri><abstract><p> Пандемия коронавирусной болезни 2019 года (COVID-19) оказала беспрецедентное воздействие на здоровье и экономику во всем мире. Прямое повреждение миокарда и цитокиновый шторм, приводящий к дестабилизации ранее существовавших бляшек и ускоренному образованию новых бляшек, являются двумя механизмами, провоцирующими острый коронарный синдром при COVID-19. Недостаточно данных об иммунном статусе пациентов с острым коронарным синдромом, перенесшим COVID-19. Целью работы явилось исследование Т- и В-клеточного, гуморального звеньев иммунитета в зависимости от числа цитотоксических Т-лимфоцитов (CD8+) у больных с острым коронарным синдромом (ОКС), перенесших COVID-19. Обследовано 65 мужчин с нестабильной стенокардией и острым инфарктом миокарда (острым коронарным синдромом) от 40 до 65 лет, которые ранее болели COVID-19. Проведено исследование периферической крови: общий анализ крови (прибор Medonic – Швеция), общие и специфические IgM, IgG, IgA, фрагменты комплимента («Вектор Бест», Россия). Субпопуляции Т- и В-лимфоцитов определены методом проточной цитометрии. У лиц с острым коронарным синдромом, перенесших COVID-19 преимущественно с нормальным и повышенным уровнями цитотоксических Т-клеток наблюдалось более тяжелое течение заболевания – превалировали больные с острым инфарктом миокарда, у них была больше смертность, продолжительность лечения, отмечались чаще тромбозы стентов. У больных с повышенными цитотоксическими Т-клетками наблюдалось максимальное увеличение эритроцитов, гемоглобина, гематокрита, лимфоцитов как общего числа, так и субпопуляций – Т-хелперов, Т-NK-лифоцитов, NK-лимфоцитов, Т-лимфоцитов ранней и поздней активации, В1- и В2-лимфоцитов, индекса НСТ-индуцированного теста. У пациентов с нормальным уровнем NK-клеток в сравнении с другими группами наблюдалось повышение НСТ спонтанной активности и индекса, значимое снижение С3а и С5а фрагментов комплемента. Превалирование тромбоза стентов и смертности в группе больных с нормальным уровнем цитотоксических Т-клеток может свидетельствовать о торпидности иммунной системы у этих пациентов с неблагоприятными исходами. Полученные данные свидетельствуют о значительной вариабельности ответов клеток иммунной системы у постковидных пациентов ОКС с различным уровнем цитотоксических клеток. Все это следует в дальнейшем рассмотреть подходы и к иммунокоррекции выявленных нарушений.</p></abstract><trans-abstract xml:lang="en"><p>The 2019 coronavirus disease (COVID-19) pandemic has had an unprecedented impact on health and economies around the world. Direct myocardial injury and cytokine storm, leading to destabilization of preexisting plaques and accelerated formation of new plaques, are two mechanisms that trigger the acute coronary syndrome in COVID-19. There is insufficient data on the immune status of patients with acute coronary syndrome who have undergone COVID-19. The aim of the study was to study T and B cell, humoral immunity depending on the number of cytotoxic T lymphocytes (CD8+) in patients with acute coronary syndrome who underwent COVID-19. Materials and methods of research: 65 men with unstable angina pectoris and acute myocardial infarction (acute coronary syndrome) from 40 to 65 years old, who had previously had COVID-19, were examined. A study of peripheral blood was carried out: complete blood count (Medonic device, Sweden), general and specific IgM, IgG, IgA, compliment fragments (Vector Best, Russia). Subpopulations of T and B lymphocytes were determined by flow cytometry. In persons with acute coronary syndrome who underwent COVID-19 with predominantly normal and elevated levels of cytotoxic T cells, a more severe course of the disease was observed: patients with acute myocardial infarction prevailed, they had longer mortality, longer treatment duration, and stent thrombosis was more common. In patients with elevated cytotoxic T cells, there was a maximum increase in erythrocytes, hemoglobin, hematocrit, lymphocytes of both the total number and subpopulations – T helpers, T-NK lymphocytes, NK lymphocytes, T lymphocytes of early and late activation, B1 and B2 lymphocytes, index of NBT-induced test. In patients with normal levels of NK cells, compared with other groups, there was an increase in spontaneous NBT activity and index, a significant decrease in C3a and C5a complement fragments. Prevalence of stent thrombosis and mortality in the group of patients with normal levels of cytotoxic T cells may indicate torpidity of the immune system in these patients with poor outcomes.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>цитотоксические Т-лимфоциты</kwd><kwd>СOVID-19</kwd><kwd>острый коронарный синдром</kwd><kwd>лимфоциты</kwd><kwd>иммунная система</kwd><kwd>комплемент</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cytotoxic T lymphocytes</kwd><kwd>СOVID-19</kwd><kwd>acute coronary syndrome</kwd><kwd>lymphocytes</kwd><kwd>immune system</kwd><kwd>complement</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal M. Cardiovascular disease and COVID-19. Diabetes Syndr., 2020, Vol. 14, no. 3, pp. 247-250.</mixed-citation><mixed-citation xml:lang="en">Bansal M. Cardiovascular disease and COVID-19. Diabetes Syndr., 2020, Vol. 14, no. 3, pp. 247-250.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Freidlin I.S. Methods for studying phagocytic cells in the evaluation human immune status: Proc. allowance. Leningrad, 1986. 37 p.</mixed-citation><mixed-citation xml:lang="en">Freidlin I.S. Methods for studying phagocytic cells in the evaluation human immune status: Proc. allowance. Leningrad, 1986. 37 p.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gang H., Peng D., Hu Y., Tang S., Li S., Huang Q. Interleukin-9-secreting CD4+ T cells regulate CD8+ T cells cytotoxicity in patients with acute coronary syndromes. APMIS, 2021, Vol. 129, no. 2, pp. 91-102.</mixed-citation><mixed-citation xml:lang="en">Gang H., Peng D., Hu Y., Tang S., Li S., Huang Q. Interleukin-9-secreting CD4+ T cells regulate CD8+ T cells cytotoxicity in patients with acute coronary syndromes. APMIS, 2021, Vol. 129, no. 2, pp. 91-102.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Khusainova L.N., Smakaeva E.R., Sadikova R.I., Mingazetdinova L.N. Cellular markers of apoptosis in acute coronary syndrome. Medical Bulletin of Bashkortostan, 2013, Vol. 8, no. 3, pp. 78-81. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Khusainova L.N., Smakaeva E.R., Sadikova R.I., Mingazetdinova L.N. Cellular markers of apoptosis in acute coronary syndrome. Medical Bulletin of Bashkortostan, 2013, Vol. 8, no. 3, pp. 78-81. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lebedeva O.K., Ermakov A.I., Gaykovaya L.B., Kukharchik G.A. Features of monocytic and lymphocytic response in myocardial infarction with symptoms of acute heart failure in patients with type 2 diabetes mellitus. Translational Medicine, 2021, Vol. 8, no. 4, pp. 5-17. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Lebedeva O.K., Ermakov A.I., Gaykovaya L.B., Kukharchik G.A. Features of monocytic and lymphocytic response in myocardial infarction with symptoms of acute heart failure in patients with type 2 diabetes mellitus. Translational Medicine, 2021, Vol. 8, no. 4, pp. 5-17. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Liu P.P., Blet A., Smyth D., Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation, 2020, Vol. 142, no. 1, pp. 68-78.</mixed-citation><mixed-citation xml:lang="en">Liu P.P., Blet A., Smyth D., Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation, 2020, Vol. 142, no. 1, pp. 68-78.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Zhao X., Zhong Y., Meng K., Yu K., Shi H., Wu B., Tony H., Zhu J., Zhu R., Peng Y., Mao Y., Cheng P., Mao X., Zeng Q. Heme oxygenase-1 restores impaired GARPCD4+CD25+ regulatory T cells from patients with acute coronary syndrome by upregulating LAP and GARP expression on activated T lymphocytes. Cell. Physiol. Biochem., 2015, Vol. 35, no. 2, pp. 553-570.</mixed-citation><mixed-citation xml:lang="en">Liu Y., Zhao X., Zhong Y., Meng K., Yu K., Shi H., Wu B., Tony H., Zhu J., Zhu R., Peng Y., Mao Y., Cheng P., Mao X., Zeng Q. Heme oxygenase-1 restores impaired GARPCD4+CD25+ regulatory T cells from patients with acute coronary syndrome by upregulating LAP and GARP expression on activated T lymphocytes. Cell. Physiol. Biochem., 2015, Vol. 35, no. 2, pp. 553-570.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Safronova E.A., Ryabova L.V. Evaluation of the population and subpopulation spectrum of lymphocytes in patients with acute coronary syndrome. Russian Journal of Immunology, 2022, Vol. 25, no. 3, pp. 313-320. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Safronova E.A., Ryabova L.V. Evaluation of the population and subpopulation spectrum of lymphocytes in patients with acute coronary syndrome. Russian Journal of Immunology, 2022, Vol. 25, no. 3, pp. 313-320. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shafeghat M., Aminorroaya A., Rezaei N. How stable ischemic heart disease leads to acute coronary syndrome in COVID-19? Acta Biomed., 2021, Vol. 92, no. 5, e2021512. doi: 10.23750/abm.v92i5.12013.</mixed-citation><mixed-citation xml:lang="en">Shafeghat M., Aminorroaya A., Rezaei N. How stable ischemic heart disease leads to acute coronary syndrome in COVID-19? Acta Biomed., 2021, Vol. 92, no. 5, e2021512. doi: 10.23750/abm.v92i5.12013.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sheth A.R., Grewal U.S., Patel H.P., Thakkar S., Garikipati S., Gaddam J., Bawa D. Possible mechanisms responsible for acute coronary events in COVID-19. Med. Hypotheses, 2020, Vol. 143, 110125. doi: 10.1016/j.mehy.2020.110125.</mixed-citation><mixed-citation xml:lang="en">Sheth A.R., Grewal U.S., Patel H.P., Thakkar S., Garikipati S., Gaddam J., Bawa D. Possible mechanisms responsible for acute coronary events in COVID-19. Med. Hypotheses, 2020, Vol. 143, 110125. doi: 10.1016/j.mehy.2020.110125.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Smirnova I.N., Antipova I.I., Titskaya E.V., Zaitsev A.A., Barabash L.V., Tonkoshkurova A.V., Zaripova T.N., Korshunov D.V. Analysis of the clinical and functional state of patients with acute coronary syndrome after endovascular interventions at the stationary stage of rehabilitation. Physiotherapy, Balneology and Rehabilitation, 2018, Vol. 17, no. 6, pp. 324-331. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Smirnova I.N., Antipova I.I., Titskaya E.V., Zaitsev A.A., Barabash L.V., Tonkoshkurova A.V., Zaripova T.N., Korshunov D.V. Analysis of the clinical and functional state of patients with acute coronary syndrome after endovascular interventions at the stationary stage of rehabilitation. Physiotherapy, Balneology and Rehabilitation, 2018, Vol. 17, no. 6, pp. 324-331. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tian X., Guo R., Zhang Y., Xu L., Liu X., Hou Y. Effects of the sympathetic nervous system on regulatory T Cell and T helper 1 chemokine expression in patients with acute coronary syndrome. Neuroimmunomodulation, 2016б, Vol. 23, no. 3, pp. 168-178.</mixed-citation><mixed-citation xml:lang="en">Tian X., Guo R., Zhang Y., Xu L., Liu X., Hou Y. Effects of the sympathetic nervous system on regulatory T Cell and T helper 1 chemokine expression in patients with acute coronary syndrome. Neuroimmunomodulation, 2016б, Vol. 23, no. 3, pp. 168-178.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zidar D.A., Mudd J.C., Juchnowski S., Lopes J.P., Sparks S., Park S.S., Ishikawa M., Osborne R., Washam J.B., Chan C., Funderburg N.T., Owoyele A., Alaiti M.A., Mayuga M., Orringer C., Costa M.A., Simon D.I., Tatsuoka C., Califf R.M., Newby L.K., Lederman M.M., Weinhold K.J. Altered maturation status and possible immune exhaustion of CD8 T lymphocytes in the peripheral blood of patients presenting with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol., 2016, Vol. 36, no. 2, pp. 389-397.</mixed-citation><mixed-citation xml:lang="en">Zidar D.A., Mudd J.C., Juchnowski S., Lopes J.P., Sparks S., Park S.S., Ishikawa M., Osborne R., Washam J.B., Chan C., Funderburg N.T., Owoyele A., Alaiti M.A., Mayuga M., Orringer C., Costa M.A., Simon D.I., Tatsuoka C., Califf R.M., Newby L.K., Lederman M.M., Weinhold K.J. Altered maturation status and possible immune exhaustion of CD8 T lymphocytes in the peripheral blood of patients presenting with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol., 2016, Vol. 36, no. 2, pp. 389-397.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
